CAMP4 Therapeutics Corporation (NASDAQ:CAMP) Stock Has Average Target Price of $9.71

by · The Cerbat Gem

Shares of CAMP4 Therapeutics Corporation (NASDAQ:CAMP – Get Free Report) have received an average rating of “Moderate Buy” from the eight research firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $10.17.

Several analysts have weighed in on CAMP shares. Piper Sandler reiterated an “overweight” rating and issued a $15.00 price objective (up from $12.00) on shares of CAMP4 Therapeutics in a research report on Friday, August 14th. Weiss Ratings raised shares of CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 17th. UBS Group set a $15.00 price target on shares of CAMP4 Therapeutics in a report on Friday, August 14th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of CAMP4 Therapeutics in a research note on Tuesday. Finally, Zacks Research raised CAMP4 Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Monday, August 17th.

Get Our Latest Research Report on CAMP4 Therapeutics

Insider Activity

In other CAMP4 Therapeutics news, Director Richard Young bought 16,378 shares of the firm’s stock in a transaction that occurred on Monday, August 3rd. The stock was bought at an average price of $1.65 per share, for a total transaction of $27,023.70. Following the completion of the acquisition, the director directly owned 186,388 shares in the company, valued at $307,540.20. The trade was a 9.63% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Andrew Schwab sold 400,000 shares of CAMP4 Therapeutics stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $4.04, for a total transaction of $1,616,000.00. Following the completion of the sale, the director owned 2,033,270 shares in the company, valued at approximately $8,214,410.80. This trade represents a 16.44% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have acquired 46,031 shares of company stock valued at $99,051 and have sold 593,613 shares valued at $2,504,037. Insiders own 21.69% of the company’s stock.

Hedge Funds Weigh In On CAMP4 Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Jupiter Topco LLC purchased a new stake in CAMP4 Therapeutics in the second quarter worth about $27,581,000. 5AM Venture Management LLC purchased a new position in shares of CAMP4 Therapeutics during the 2nd quarter worth approximately $25,647,928. Trails Edge Capital Partners LP bought a new position in shares of CAMP4 Therapeutics in the 2nd quarter worth approximately $8,446,935. BlackRock Inc. bought a new position in shares of CAMP4 Therapeutics in the 2nd quarter worth approximately $7,185,000. Finally, EcoR1 Capital LLC purchased a new position in shares of CAMP4 Therapeutics in the 4th quarter valued at approximately $1,992,000.

CAMP4 Therapeutics Trading Up 4.2%

Shares of NASDAQ:CAMP opened at $4.00 on Wednesday. The stock’s 50-day moving average price is $4.16 and its 200-day moving average price is $4.26. CAMP4 Therapeutics has a 12-month low of $2.86 and a 12-month high of $7.75. The stock has a market capitalization of $251 million, a P/E ratio of -1.72 and a beta of 0.27.

CAMP4 Therapeutics (NASDAQ:CAMP – Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The Wireless communications provider reported ($0.58) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.34). CAMP4 Therapeutics had a negative return on equity of 252.79% and a negative net margin of 2,543.74%.The company had revenue of $1.78 million during the quarter. As a group, research analysts predict that CAMP4 Therapeutics will post -0.57 EPS for the current year.

About CAMP4 Therapeutics

(Get Free Report)

CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company developing RNA-based medicines for genetic diseases caused by insufficient expression of essential proteins. The company’s approach is designed to increase the body’s production of naturally occurring proteins by activating the transcription of specific genes, potentially addressing the underlying cause of disease rather than only treating symptoms.

CAMP4’s technology platform uses RNA-based gene-activation therapeutics intended to target regulatory regions associated with disease-relevant genes.

See Also